Organogenesis Holdings Inc (ORGO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Organogenesis Holdings Inc (ORGO) has a cash flow conversion efficiency ratio of 0.008x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($3.08 Million) by net assets ($385.98 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Organogenesis Holdings Inc's balance sheet to measure how much of total assets are equity-financed.
Organogenesis Holdings Inc - Cash Flow Conversion Efficiency Trend (2001–2024)
This chart illustrates how Organogenesis Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is Organogenesis Holdings Inc's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Organogenesis Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Organogenesis Holdings Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Gigasolar Materials
TWO:3691
|
-0.036x |
|
Akebia Ther
NASDAQ:AKBA
|
0.955x |
|
Jiangsu Canopus Wisdom Medical Technology Co. Ltd. A
SHE:301290
|
N/A |
|
Chemclin Diagnostics Co. Ltd. A
SHG:688468
|
0.024x |
|
APAC Opto Electronics
TWO:4908
|
0.029x |
|
Zbom Cabinets Co Ltd
SHG:603801
|
0.089x |
|
HCK Capital Group Bhd
KLSE:7105
|
-0.259x |
|
Panda Dairy Corp
SHE:300898
|
0.056x |
Annual Cash Flow Conversion Efficiency for Organogenesis Holdings Inc (2001–2024)
The table below shows the annual cash flow conversion efficiency of Organogenesis Holdings Inc from 2001 to 2024. For the full company profile with market capitalisation and key ratios, see Organogenesis Holdings Inc (ORGO) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $385.32 Million | $14.21 Million | 0.037x | -66.76% |
| 2023-12-31 | $278.66 Million | $30.92 Million | 0.111x | +18.57% |
| 2022-12-31 | $265.67 Million | $24.86 Million | 0.094x | -63.56% |
| 2021-12-31 | $241.34 Million | $61.98 Million | 0.257x | +566.27% |
| 2020-12-31 | $141.81 Million | $5.47 Million | 0.039x | +106.39% |
| 2019-12-31 | $55.58 Million | $-33.53 Million | -0.603x | +53.28% |
| 2018-12-31 | $47.04 Million | $-60.74 Million | -1.291x | -65496.73% |
| 2017-12-31 | $298.01 Million | $-586.60K | -0.002x | -5.07% |
| 2016-12-31 | $300.11 Million | $-562.23K | -0.002x | -100.00% |
| 2015-12-31 | $-162.00 | $-10.19 Million | 62919.753x | +9389980.80% |
| 2001-12-31 | $-2.08 Million | $-1.40 Million | 0.670x | -- |
About Organogenesis Holdings Inc
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barrier… Read more